|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-4-29
|
|
pubmed:abstractText |
To elicit a therapeutic antitumor immune response, dendritic cells (DCs) have been employed as a cellular adjuvant. Among various DC-based approaches, fusion of DCs and tumor cells potentially confers not only DC functionality, but also a continuous source of unaltered tumor antigens. We have recently demonstrated successful generation of fusion hybrids by a large-scale electrofusion technique. The immunogenicity and therapeutic potential of fusion hybrids were further analyzed in a model system of a murine melanoma cell line expressing beta-galactosidase (beta-gal) as a surrogate tumor antigen. A single vaccination with fusion hybrids plus IL-12 induced a therapeutic immune response against 3-day established pulmonary metastases. This immunotherapy was beta-gal specific and involved both CD4 and CD8 T cells. In vitro, fusion hybrids stimulated specific IFN-gamma secretion from both CD4 and CD8 immune T cells. They also nonspecifically induced IL-10 secretion from CD4 but not CD8 T cells. Compared to other DC loadings, our results demonstrate the superior immunogenicity of fusion. The current technique of electrofusion is adequately developed for clinical use in cancer immunotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-8749
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
220
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1-12
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12718934-Adjuvants, Immunologic,
pubmed-meshheading:12718934-Animals,
pubmed-meshheading:12718934-Antigen Presentation,
pubmed-meshheading:12718934-CD4-Positive T-Lymphocytes,
pubmed-meshheading:12718934-CD8-Positive T-Lymphocytes,
pubmed-meshheading:12718934-Cancer Vaccines,
pubmed-meshheading:12718934-Cell Fusion,
pubmed-meshheading:12718934-Combined Modality Therapy,
pubmed-meshheading:12718934-Dendritic Cells,
pubmed-meshheading:12718934-Electric Stimulation,
pubmed-meshheading:12718934-Female,
pubmed-meshheading:12718934-Hybrid Cells,
pubmed-meshheading:12718934-Immunologic Factors,
pubmed-meshheading:12718934-Immunotherapy,
pubmed-meshheading:12718934-Interferon-gamma,
pubmed-meshheading:12718934-Interleukin-10,
pubmed-meshheading:12718934-Interleukin-12,
pubmed-meshheading:12718934-Lung Neoplasms,
pubmed-meshheading:12718934-Melanoma, Experimental,
pubmed-meshheading:12718934-Mice,
pubmed-meshheading:12718934-Mice, Inbred C57BL,
pubmed-meshheading:12718934-Neoplastic Stem Cells,
pubmed-meshheading:12718934-Recombinant Fusion Proteins,
pubmed-meshheading:12718934-Specific Pathogen-Free Organisms,
pubmed-meshheading:12718934-Vaccination,
pubmed-meshheading:12718934-beta-Galactosidase
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Therapeutic immune response induced by electrofusion of dendritic and tumor cells.
|
|
pubmed:affiliation |
Center for Surgery Research-FF50, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
